Septic Shock News and Research

RSS

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results, French researchers report at the 2nd European Lung Cancer Conference.

3 May 2010

Medinox, Orient Europharma form partnering agreement for NOX-100 anti-hypotensive drug

Medinox, Inc. in Carlsbad, California and Orient Europharma in Taiwan announce today that they have entered into a partnering agreement to develop and market NOX-100, a new anti-hypotensive drug. Under the terms of the agreement, Orient Europharma holds the exclusive distribution rights of NOX-100 in Taiwan, China, Korea, Australia, New Zealand and Southeast Asia. Medinox retains the marketing rights in the United States, Japan and Europe.

12 Apr 2010

Indispensable role of Mindin in innate and adaptive immunity

Mindin has an indispensable role in both innate and adaptive immunity. A research group in China investigated regulation of mindin expression and the signaling pathway involved. mRNA expression of mindin was upregulated during dextran sulfate sodium induced mouse intestinal inflammation. Stimulation with CpG-ODN (a known TLR-9 ligand) induced upregulation of mindin expression in RAW 264.7 cells and significantly increased the NF-κB-luciferase activity in vitro.

31 Mar 2010

Shock: Norepinephrine favored over dopamine

Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).

3 Mar 2010

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

BioMS Medical Corp. today reported that Spectral Diagnostics has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxin(TM), a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxin(TM) in the United States.

3 Mar 2010

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Spectral Diagnostics Inc., a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing the Company to conduct a pivotal trial in the United States.

2 Mar 2010

Study on new drug targets for prevention of tissue inflammation after stroke

Researchers at Albany Medical College are releasing results of a study this week that they say will help refocus the search for new drug targets aimed at preventing or reversing the devastating tissue inflammation that results after heart attack and stroke.

1 Mar 2010

Comparison study of two treatment strategies for severe sepsis reveals similar short-term survival rates

A comparison of two strategies for treating severe sepsis or septic shock finds that using lactate levels measured in blood samples showed a similar short-term survival rate compared to a treatment regimen using central venous oxygen saturation measured using a specialized catheter, according to a study in the February 24 issue of JAMA.

24 Feb 2010

Treating septic shock patients with intensive insulin therapy does not reduce risk of in-hospital death

Treating adults with septic shock with intensive insulin therapy to counter elevated blood glucose levels associated with corticosteroid therapy did not result in a reduced risk of in-hospital death, compared to patients who received conventional insulin therapy, according to a study in the January 27 issue of JAMA.

27 Jan 2010

Decline in hospital mortality rate linked to participation in Sepsis Campaign

A reduction in hospital mortality from severe sepsis and septic shock was associated with participation in the Surviving Sepsis Campaign performance improvement initiative, according to an article published simultaneously in the February issues of Critical Care Medicine and Intensive Care Medicine and posted ahead of print at www.ccmjournal.com.

18 Jan 2010

Nitric oxide opens up new treatment option for septic shock

Scientists at VIB and Ghent University in Flanders, Belgium have found an unexpected ally for the treatment of septic shock, the major cause of death in intensive care units.

16 Dec 2009

Financial results for third-quarter 2009 announced by Spectral Diagnostics

Spectral Diagnostics Inc., today announced its financial results for the third quarter ended September 30, 2009.

12 Nov 2009

'Hormone of darkness' melatonin regulates sleep effectively

Melatonin, a natural hormone segregated by the own human body, is an excellent sleep regulator expected to replace somniferous, which are much more aggressive, to correct the sleep/wakefulness pace when human biological clock becomes altered.

6 Nov 2009

Appropriate initial antimicrobial therapy reduces mortality in patients with septic shock

Patients experiencing septic shock who receive inappropriate therapy may have a fivefold reduction in survival, shows a new study. Researchers from the University of Manitoba, Winnipeg, MB, Canada, retrospectively reviewed the cases of 5,715 patients with septic shock to determine the appropriateness of initial antimicrobial therapy, clinical infection site, and relevant pathogens.

5 Nov 2009

Researchers study functional similarity between zebrafish and humans to fight infections

Since the human response to infection is highly complex, research to understand how people fight infection is facilitated by studying how similar processes occur in simpler organisms. Zebrafish are becoming an important model for human disease, since they are easily handled, maintained and manipulated and many fundamental processes between zebrafish and humans are conserved.

24 Sep 2009

Spacelabs Healthcare launches Ultrasonic Cardiac Output Monitor in international markets

Spacelabs Healthcare today announced the launch of the Ultrasonic Cardiac Output Monitor (USCOM) in several new geographies, including Latin America, Africa, Europe, Australia and Middle East. USCOM’s unique and totally non-invasive method of cardiac monitoring provides an accurate, safe and efficient way of measuring how well the heart is functioning.

27 Aug 2009

ARIAD's petition for rehearing the Lilly NF-Kb patent lawsuit is granted by the Federal Circuit

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and its co-plaintiffs today announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) has granted their petition for rehearing en banc and has vacated its April 2009 decision in the appeal that Eli Lilly and Co. filed in 2008. All twelve judges of the Federal Circuit will now rehear and reassess the merits of Lilly’s appeal.

24 Aug 2009

Senior men more likely than women to die after pneumonia

Differing biological response to infection between men and women may explain higher death rates among older men who are hospitalized with community-acquired pneumonia (CAP).

29 Apr 2009

Researchers block immune cell rush behind deadly sepsis

Researchers have found a way to block the ability of white blood cells to sprint toward the sites of infection when such speed worsens the damage done by sepsis, the often fatal, whole-body bacterial infection, according to a study published today in the journal Blood.

24 Feb 2009